NASDAQ:ACET

Adicet Bio (ACET) Stock Forecast, Price & News

$1.46

-0.07 (-4.58%)

(As of 09/22/2023 08:51 PM ET)

Compare

Today's Range: $1.45
▼
$1.58
50-Day Range: $1.46
▼
$3.22
52-Week Range: $1.45
▼
$21.87

Volume: 303,600 shs
Average Volume: 635,543 shs
Market Capitalization: $62.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.50

Adicet Bio MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 1,098.6% Upside
$17.50 Price Target
Short Interest: Bearish
8.95% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$1.84 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.93) to ($2.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

168th out of 961 stocks

Pharmaceutical Preparations Industry

60th out of 455 stocks

4.3

Analyst's Opinion

Consensus Rating
Adicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.50, Adicet Bio has a forecasted upside of 1,098.6% from its current price of $1.46.
Amount of Analyst Coverage
Adicet Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
8.95% of the float of Adicet Bio has been sold short.
Short Interest Ratio / Days to Cover
Adicet Bio has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Adicet Bio has recently increased by 9.31%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Adicet Bio does not currently pay a dividend.
Dividend Growth
Adicet Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACET.

1.1

News and Social Media Coverage

Search Interest
6 people have searched for ACET on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
MarketBeat Follows
2 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adicet Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,840,750.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
29.50% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
85.29% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Adicet Bio are expected to grow in the coming year, from ($2.93) to ($2.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adicet Bio is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adicet Bio is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adicet Bio has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Adicet Bio (NASDAQ:ACET) Stock

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.

ACET Price History

30 days | 90 days | 365 days | Advanced Chart

ACET Stock News Headlines

September 6, 2023 | msn.com

Truist Securities Reiterates Adicet Bio (ACET) Buy Recommendation

August 12, 2023 | finance.yahoo.com

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

September 25, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

August 11, 2023 | msn.com

BTIG Maintains Adicet Bio (ACET) Buy Recommendation

August 9, 2023 | finance.yahoo.com

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue Estimates

August 9, 2023 | markets.businessinsider.com

Adicet Bio, Inc Q2 Loss increases, misses estimates

August 9, 2023 | finance.yahoo.com

Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 3, 2023 | finance.yahoo.com

Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference

September 25, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

July 12, 2023 | benzinga.com

Adicet Bio Director Awarded $236K Worth of Stock Options

July 11, 2023 | finance.yahoo.com

Adicet Announces Appointment of Katie Peng to the Board of Directors

July 6, 2023 | msn.com

Adicet Bio (ACET) Price Target Decreased by 12.90% to 24.48

June 30, 2023 | benzinga.com

Massive Insider Trade At Adicet Bio

June 30, 2023 | benzinga.com

Director of Adicet Bio Purchased $1.83M In Stock

June 27, 2023 | msn.com

JMP downgrades Adicet to market perform, citing study delay

June 27, 2023 | msn.com

Adicet Bio Stock Craters 54% after JMP Downgrade

June 27, 2023 | markets.businessinsider.com

Analyst Downgrades Adicet Citing Uncertainty, Awaits Long-Term Data On Durability

June 27, 2023 | markets.businessinsider.com

6 Analysts Have This to Say About Adicet Bio

June 27, 2023 | msn.com

MoonLake Immunotherapeutics, Applied Digital And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

June 27, 2023 | markets.businessinsider.com

Adicet Bio (ACET) was downgraded to a Hold Rating at JMP Securities

June 27, 2023 | benzinga.com

Adicet Bio Stock Is Falling Premarket - Here's Why

June 13, 2023 | markets.businessinsider.com

JonesTrading Reaffirms Their Buy Rating on Adicet Bio (ACET)

June 2, 2023 | msn.com

JP Morgan Downgrades Adicet Bio (ACET)

June 1, 2023 | finance.yahoo.com

Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference

May 18, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Adicet Bio (ACET)

May 18, 2023 | msn.com

Adicet Bio's Cancer Candidate Shows Anti-Tumor Activity In Preclinical Study

May 18, 2023 | finance.yahoo.com

Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

See More Headlines

Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

ACET Company Calendar

Last Earnings: 8/09/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Trading Companies & Distributors
Sector: Medical
Current Symbol: NASDAQ:ACET
CUSIP: 00444610
CIK: 2034
Web: www.aceto.com
Phone: (650) 503-9095
Fax: N/A
Employees: 132
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.50
High Stock Price Forecast: $27.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +1,098.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,790,000.00
Net Margins: N/A
Pretax Margin: -279.27%
Return on Equity: -41.30%
Return on Assets: -36.34%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.08
Quick Ratio: 11.08

Sales & Book Value

Annual Sales: $24.99 million
Price / Sales: 2.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.82 per share
Price / Book: 0.21

Miscellaneous

Outstanding Shares: 43,070,000
Free Float: 30,362,000
Market Cap: $62.88 million
Optionable: Optionable
Beta: 1.96

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Chen Schor BA (Age 51)
CPA, CPA, M.B.A., MBA, CEO, Pres & Director
Comp: $899.58k

Dr. Aya Jakobovits Ph.D. (Age 68)
Founder & Independent Director
Comp: $40k

Dr. Blake Aftab Ph.D. (Age 42)
Sr. VP & Chief Scientific Officer
Comp: $675.04k

Dr. Francesco Galimi M.D. (Age 55)
Ph.D., Chief Medical Officer & Sr. VP
Comp: $680.37k

Mr. Brian Nicholas Harvey (Age 62)
Chief Financial Officer

Dr. Donald Healey Ph.D. (Age 61)
Chief Technology Officer

Ms. Amy Locke
Head of HR

Dr. Nancy L. Boman M.D.
Ph.D., Sr. VP & Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACET Stock - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACET shares.
View ACET analyst ratings or view top-rated stocks.
What is Adicet Bio's stock price forecast for 2023?: 7 Wall Street research analysts have issued 12 month target prices for Adicet Bio's shares. Their ACET share price forecasts range from $6.00 to $27.00. On average, they predict the company's share price to reach $17.50 in the next year. This suggests a possible upside of 1,098.6% from the stock's current price.
View analysts price targets for ACET or view top-rated stocks among Wall Street analysts.
How have ACET shares performed in 2023?: Adicet Bio's stock was trading at $8.94 on January 1st, 2023. Since then, ACET stock has decreased by 83.7% and is now trading at $1.46.
View the best growth stocks for 2023 here.
When is Adicet Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ACET earnings forecast.
How were Adicet Bio's earnings last quarter?: Adicet Bio, Inc. (NASDAQ:ACET) announced its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.07.
What other stocks do shareholders of Adicet Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

What is Adicet Bio's stock symbol?: Adicet Bio trades on the NASDAQ under the ticker symbol "ACET."
Who are Adicet Bio's major shareholders?: Adicet Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cowen AND Company LLC (6.60%), BlackRock Inc. (5.56%), Candriam S.C.A. (1.67%), Geode Capital Management LLC (1.47%), Decheng Capital Management III Cayman LLC (1.18%) and Dimensional Fund Advisors LP (0.77%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Carl L Gordon, Chen Schor, Don Healey, Francesco Galimi, Jay P Elliott and Steve Dubin.
View institutional ownership trends.
How do I buy shares of Adicet Bio?: Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Adicet Bio's stock price today?: One share of ACET stock can currently be purchased for approximately $1.46.
How much money does Adicet Bio make?: Adicet Bio (NASDAQ:ACET) has a market capitalization of $62.88 million and generates $24.99 million in revenue each year. The company earns $-69,790,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis.
How many employees does Adicet Bio have?: The company employs 132 workers across the globe.
How can I contact Adicet Bio?: Adicet Bio's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The official website for the company is www.aceto.com. The company can be reached via phone at (650) 503-9095 or via email at jburfening@lhai.com.

This page (NASDAQ:ACET) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adicet Bio (ACET) Stock Forecast, Price & News

Adicet Bio MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Adicet Bio (NASDAQ:ACET) Stock

ACET Price History

ACET Stock News Headlines

ACET Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ACET Stock - Frequently Asked Questions

Overall MarketRank^™